NOW INDICATED FOR AAA PATIENTS WITH HIGHLY ANGULATED NECKS

W. L. Gore & Associates (Gore) announces FDA approval of an expanded indication for the GORE® EXCLUDER® Conformable AAA Endoprosthesis, now indicated for patients with aortic neck angulation ≤ 90° and a minimum length of 10 mm.

Apr 30, 2024

W. L. GORE & ASSOCIATES, INC. RECEIVES U.S. FOOD & DRUG ADMINISTRATION (FDA) APPROVAL FOR LOWER PROFILE <strong>GORE® VIABAHN® VBX</strong> BALLOON EXPANDABLE ENDOPROSTHESIS, NOW 6 FR SHEATH COMPATIBLE

Jan 31, 2024

GORE RECEIVES FDA APPROVAL FOR BREAKTHROUGH ENDOVASCULAR DEVICE IN COMPLEX AORTIC ANEURYSMS

First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral aorta.

Jan 25, 2024

FIRST PATIENTS ENROLLED IN THE GORE VBX FORWARD CLINICAL STUDY

Jan 16, 2024

GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE^® ASCENDING STENT GRAFT

CAUTION: Investigational device. Limited by United States law to investigational use.

Dec 20, 2023

THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

CAUTION: Investigational device. Limited by United States law to investigational use.

Oct 15, 2023

GORE INITIATES STUDY TO COMPARE THE GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS TO BARE METAL STENTS

Jun 13, 2023

GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE® VIAFORT VASCULAR STENT ILIOFEMORAL STUDY

CAUTION: Investigational device. Limited by United States law to investigational use.

Jun 6, 2023

GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE^® VIAFORT VASCULAR STENT IVC STUDY

CAUTION: Investigational device. Limited by United States law to investigational use.

Mar 28, 2023

GORE INITIATES THE RELIEF CLINICAL STUDY EVALUATING PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF

CAUTION: Investigational device. Limited by United States law to investigational use.

Nov 1, 2022